Impact of tumor sequencing on the use of anticancer drugs.
作者： François Thomas , Christine Desmedt , Philippe Aftimos , Ahmad Awada
DOI: 10.1097/CCO.0000000000000078
关键词:
摘要: PURPOSE OF REVIEW: Next generation sequencing (NGS) allows the rapid analysis of genomes and has brought invaluable information on cancer biology drug targets. Laboratories have started to provide NGS data physicians aid in prescription targeted drugs. The review presents recent clinical experience with NGS. RECENT FINDINGS: Clinical studies support potential tailor treatment patients alterations their genome a process called precision medicine. Case reports, analyses early phase trials, series lung recently shown superior outcome for matching specific molecular alterations. is also useful detect germline mutations associated hereditary cancers. SUMMARY: other technologies are transforming practice medical oncology research. Sequencing primary tumors, metastases, or blood-derived circulating tumor DNA great guide individualized treatment. However, integration as breakthrough technology operational challenges such processing, education interpretation, reimbursement. ? 2014 Wolters Kluwer Health.
ulb.ac.be
wkhealth.com参考文章(59)
Iris Schrijver, Nazneen Aziz, Daniel H. Farkas, Manohar Furtado, Andrea Ferreira Gonzalez, Timothy C. Greiner, Wayne W. Grody, Tina Hambuch, Lisa Kalman, Jeffrey A. Kant, Roger D. Klein, Debra G.B. Leonard, Ira M. Lubin, Rong Mao, Narasimhan Nagan, Victoria M. Pratt, Mark E. Sobel, Karl V. Voelkerding, Jane S. Gibson, Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. The Journal of Molecular Diagnostics. ,vol. 14, pp. 525- 540 ,(2012) , 10.1016/J.JMOLDX.2012.04.006
Edward S Kim, Roy S Herbst, Ignacio I Wistuba, J Jack Lee, George R Blumenschein Jr, Anne Tsao, David J Stewart, Marshall E Hicks, Jeremy Erasmus Jr, Sanjay Gupta, Christine M Alden, Suyu Liu, Ximing Tang, Fadlo R Khuri, Hai T Tran, Bruce E Johnson, John V Heymach, Li Mao, Frank Fossella, Merrill S Kies, Vassiliki Papadimitrakopoulou, Suzanne E Davis, Scott M Lippman, Waun K Hong, None, The BATTLE Trial: Personalizing Therapy for Lung Cancer Cancer Discovery. ,vol. 1, pp. 44- 53 ,(2011) , 10.1158/2159-8274.CD-10-0010
Rachael Natrajan, Jorge S Reis-Filho, Next-generation sequencing applied to molecular diagnostics Expert Review of Molecular Diagnostics. ,vol. 11, pp. 425- 444 ,(2011) , 10.1586/ERM.11.18
Levi A. Garraway, Genomics-Driven Oncology: Framework for an Emerging Paradigm Journal of Clinical Oncology. ,vol. 31, pp. 1806- 1814 ,(2013) , 10.1200/JCO.2012.46.8934
Samuel Aparicio, Carlos Caldas, None, The Implications of Clonal Genome Evolution for Cancer Medicine The New England Journal of Medicine. ,vol. 368, pp. 842- 851 ,(2013) , 10.1056/NEJMRA1204892
Frédérique Nowak, Jean-Charles Soria, Fabien Calvo, Tumour molecular profiling for deciding therapy-the French initiative. Nature Reviews Clinical Oncology. ,vol. 9, pp. 479- 486 ,(2012) , 10.1038/NRCLINONC.2012.42
G. Iyer, A. J. Hanrahan, M. I. Milowsky, H. Al-Ahmadie, S. N. Scott, M. Janakiraman, M. Pirun, C. Sander, N. D. Socci, I. Ostrovnaya, A. Viale, A. Heguy, L. Peng, T. A. Chan, B. Bochner, D. F. Bajorin, M. F. Berger, B. S. Taylor, D. B. Solit, Genome Sequencing Identifies a Basis for Everolimus Sensitivity Science. ,vol. 338, pp. 221- 221 ,(2012) , 10.1126/SCIENCE.1226344
J. Kaiser, Rare Cancer Successes Spawn 'Exceptional' Research Efforts Science. ,vol. 340, pp. 263- 263 ,(2013) , 10.1126/SCIENCE.340.6130.263
Eric S Lander, None, Initial impact of the sequencing of the human genome Nature. ,vol. 470, pp. 187- 197 ,(2011) , 10.1038/NATURE09792
Eugene Fratkin, Sivan Bercovici, Dietrich A Stephan, The implications of ENCODE for diagnostics. Nature Biotechnology. ,vol. 30, pp. 1064- 1065 ,(2012) , 10.1038/NBT.2418